**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Efstathios Kastritis
Department of Clinical Therapeutics, National and Kapodistrian University of Athens Medical School, Athens, Greece

**Main Body of the Abstract**
Background: Wild type cardiac transthyretin amyloidosis (wtATTR) is an age-related disease with adverse prognosis and increasing incidence. ATTR may adversely affect vascular function and accelerate vascular aging. Tafamidis, a TTR stabilizer, improves prognosis; however, whether tafamidis exerts any effect on vascular aging processes is unknown.
Methods: This is an observational, prospective study enrolling wtATTR patients receiving tafamidis. Patients were evaluated at baseline, 3, 6 and 12 months for markers of vascular aging including pulse wave velocity (PWV), and non-invasive pulse wave analysis. ATTR patients were compared to non-amyloidosis  elderly controls (N=30, age>70 years) who were assessed at baseline and 12 months.
Results: Twenty-one patients with wtATTR receiving tafamidis were recruited. PWV decreased compared to baseline, in patients receiving tafamidis [baseline vs a) 3 months: -0.95 m/s (95%CI -1.73, -0.159), b) 6 months: -1.36 m/s (95%CI -2.19, -0.54), c) 1 year: -1.08 m/s (95%CI -2.03, -0.12), p-value<0.01 for all]. Compared to controls, baseline PWV did not differ (12.48 m/s vs 12.21 m/s). However, in the  control group PWV increased significantly after 1 year (mean change: 1.33 m/s, (95%CI 0.51, 2.15), p-value=0.024), while PWV was significantly lower in wtATTR group after 1 year compared to the control group(p for interaction=0.0089).  Central systolic blood pressure decreased after 6 months of treatment and returned to baseline levels after 1 year [6 months: -5.95 mmHg (95%CI -10.31, -1.60) p-value=0.007, 1 year: -0.47 mmHg (95%CI -5.42, 4.49), p-value=0.854].
Conclusion: Tafamidis may delay vascular aging in patients with wtATTR without affecting central hemodynamics



**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Efstathios Kastritis
Department of Clinical Therapeutics, National and Kapodistrian University of Athens Medical School, Athens, Greece

**Main Body of the Abstract**
**Background:** Wild type cardiac transthyretin amyloidosis (wtATTR) is an age-related disease with adverse prognosis and increasing incidence. ATTR may adversely affect vascular function and accelerate vascular aging. Tafamidis, a TTR stabilizer, improves prognosis; however, whether tafamidis exerts any effect on vascular aging processes is unknown.
**Methods:** This is an observational, prospective study enrolling wtATTR patients receiving tafamidis. Patients were evaluated at baseline, 3, 6 and 12 months for markers of vascular aging including pulse wave velocity (PWV), and non-invasive pulse wave analysis. ATTR patients were compared to non-amyloidosis  elderly controls (N=30, age>70 years) who were assessed at baseline and 12 months.
**Results:** Twenty-one patients with wtATTR receiving tafamidis were recruited. PWV decreased compared to baseline, in patients receiving tafamidis [baseline vs a) 3 months: -0.95 m/s (95%CI -1.73, -0.159), b) 6 months: -1.36 m/s (95%CI -2.19, -0.54), c) 1 year: -1.08 m/s (95%CI -2.03, -0.12), p-value<0.01 for all]. Compared to controls, baseline PWV did not differ (12.48 m/s vs 12.21 m/s). However, in the  control group PWV increased significantly after 1 year (mean change: 1.33 m/s, (95%CI 0.51, 2.15), p-value=0.024), while PWV was significantly lower in wtATTR group after 1 year compared to the control group(p for interaction=0.0089).  Central systolic blood pressure decreased after 6 months of treatment and returned to baseline levels after 1 year [6 months: -5.95 mmHg (95%CI -10.31, -1.60) p-value=0.007, 1 year: -0.47 mmHg (95%CI -5.42, 4.49), p-value=0.854].
**Conclusion:** Tafamidis may delay vascular aging in patients with wtATTR without affecting central hemodynamics



The effect of tafamidis treatment on vascular aging in patients with ATTR cardiomyopathy. An observational study PC61 (#310)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.